Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic ...

In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver ...

MAIA Biotechnology, Inc.: MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ...
ABC7 KABC

NORAD continues decades-long tradition of tracking Santa's trip around the world

While Santa is no threat, the same combination of radar, satellites and jets that help NORAD carry out its mission throughout the year make it capable of tracking the progress of Santa starting from ...
vornews

Minnesota Mayors Press Walz for Answers as Federal Probe Ramps Up

A wide federal investigation into suspected fraud across Minnesota social services has hit a new peak. Whistleblowers inside ...